We believe pharma and device companies make a huge difference in human lives. We believe patient/physician relationship should be based on 100% trust. Therefore, We believe and support global transparency movement. Our solutions make compliance with transparency and other regulations a welcome breeze.
View, monitor and analyze all your compliance data in one place.
Multichannel solution to better manage consent, disputes and pre-disclosure review.
Market and competitor intelligence at your fingertips.
What spend are you going to report under Sunshine Payments or EFPIA? Do you know what is in your data?
What will a journalist conclude when they access your public spend records? What will the OIG find as they look for co-relation in spend and Med Part D data under their 2017 work plan?
Let qordata Compliance Insights give you visibility into your own spend. It’s the kind of visibility the CMS/DOJ world wish for.
The latest Pharmaceutical Compliance, Transparency and Analytics insights from around the world, now at your fingertips. Get expert solutions to your specific Pharma Spend Issues.SIGN UP AS AN EXPERT
Efficiency and Foresight: The qordata Advantage For Zimmer Biomet
For Zimmer Biomet, Compliance Insights, a dedicated CMS Open Payments Solution, was an affirmative response to both. Within a short period, Zimmer Biomet recorded 50% cost reduction and a corresponding error rate reduction. It achieved quantifiable savings in time, efficiency, and gained better insights.DOWNLOAD
Helping thousands of people and companies communicate and work better.
qordata Releases Open Payments Data 2016
Princeton, New Jersey: qordata has released Open Payments Data 2016 less than 24 hours after the publication of 11.96 million financial transactions, (US $ value 8.18 billion) on the CMS Website.READ FULL STORY
Thought Leadership —Transparency, Insights And Disclosure
Under the GDPR, one of the key requirements is that controllers are required to manage consent with the HCPs that they engage with, at any level now as opposed to acquiring consent “only” for data publishing under the transparency directive. Browsing through industry experts and teams establishing consent management within their organisations, I believe we can plot stages at which most of the pharmaceutical drug and device manufacturers within the EU are placed at, with respect to managing their consent programs. Here is what it looks like, so far: Stages depicted in terms of an organization’s process maturity towards capturing, revoking and managing other areas of consent, under the GDPR: Stage 0: No consent management program or not required Stage […]
According to the GDPR (Article 4, Section 12): “Personal data breach means a breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to, personal data transmitted, stored or otherwise processed.” Why data breach is a big deal? Because a single breach can result in, but not just limited to: Loss of control over personal data; Limitation of rights Discrimination; Identity theft Fraud; Financial loss Unauthorised reversal of pseudonymization Reputational damage; Loss of confidentiality protected by professional secrecy Only recently, we witnessed data breach in transport industry in Sweden, an accidental disclosure of customer data. And another, that is one of the largest breaches, in the UK was witnessed a couple of months […]
A few weeks ago, as we briefly covered news on Insys Therapeutics, we realized that the ripples of its scandal would be felt across the pond. And indeed, qordata finds many compliance professionals in the EU pharma industry voicing concerns about the possibility of something like this happening in their own markets. The fact that many markets in EU allow physicians to not give publishing consent means that transparency vis-à-vis individual spend is limited. In other words, compliance concerns are not entirely unwarranted. For medical drug and device companies in the EU, the lessons from Insys are obvious: Lesson#1: Pharma Scandals Never Die. (And they don’t always fade away either): Media woes for Insys Therapeutics have been around since at […]